autoimmune diseases

News

Ouro makes debut with $120m for autoimmune disease TCEs

Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for autoimmune diseases.

Oncology

Transforming autoimmune disease therapy: Post-ACR 2024 persp...

The 2024 American College of Rheumatology (ACR) annual meeting spotlighted transformative advancements in cell therapies for autoimmune diseases, with chimeric antigen receptor (CAR)-T ther

News

Roche buys off-the-shelf CAR-T player Poseida for $1bn

Roche has upgraded its partnership with off-the-shelf CAR-T therapy specialist Poseida to a $1 billion-plus takeover bid

News

Novartis pays $150m upfront for Monte Rosa degrader drug

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion.

News

J&J launches gMG market bid with nipocalimab filing

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete wit

News

Dr Fred Aslan, Artiva's president and chief executive

Artiva announces terms for its second IPO attempt

After abandoning its first initial public offering (IPO) filed in 2021, natural killer (NK) cell therapy specialist Artiva Biotherapeutics is having another go.

Ouro makes debut with $120m for autoimmune disease TCEs

Transforming autoimmune disease therapy: Post-ACR 2024 persp...

Roche buys off-the-shelf CAR-T player Poseida for $1bn

Novartis pays $150m upfront for Monte Rosa degrader drug

J&J launches gMG market bid with nipocalimab filing

Artiva announces terms for its second IPO attempt

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

autoimmune diseases

Editor's Picks